The effectiveness of alteplase and urokinase in restoring adequate hemodialysis blood-flow rates was examined. A retrospective review of the medical records of hemodialysis patients with central ...
In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...
PURPOSE: To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS: The study design was a phase III, open-label, ...
In the wake of recently announced shortages in the availability of Cathflo® Activase®, commonly used to restore patency in occluded catheters1, ICU Medical, Inc. ICUI said that its Neutron catheter ...
Discover comprehensive details about Alteplase, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
We conducted a study of patients with acute pulmonary embolism and pulmonary hypertension or right ventricular dysfunction but without arterial hypotension or shock. The patients were randomly ...
The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor. Actilyse Cathflo contains the active ingredient alteplase. It belongs in the ...
Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase. Bolus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results